Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

anti-Mouse Cytokeratin 17, DyLight 680, Clone: E3, Novus Biologicals™

Manufacturer:  Novus BiologicalsSupplier Diversity Partner NBP233188FR

Catalog No. NBP233188FR

This item has been discontinued by the manufacturer and is no longer available. Please call customer service for assistance: 1-800-766-7000.


Specifications

Specifications

Cytokeratin 17
E3 (same as Ks17.E3)
ELISA
Purified
KRT17
The cytoskeletal fraction of rat colon epithelium was used as immunogen for the Cytokeratin 17 E3 antibody.
46 kDa
0.1 ml
Cancer
Primary
3872
Human, Rat, Porcine, Bovine, Goat
ELISA
DyLight 680
50mM Sodium Borate with 0.05% Sodium Azide
39.1, CK-17, cytokeratin-17, K17, keratin 17, keratin, type I cytoskeletal 17, keratin-17, PC, PC2, PCHC1
Mouse
IgG2b Kappa
Protein G purified
RUO
Store at 4C in the dark.
Monoclonal
Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFP's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
Documents
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

For Research Use Only